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Recognition that exposure to environmental
estrogens may cause adverse reproductive
effects led to the development of assays capa-
ble of detecting such compounds. These
include in vitro assays, such as binding to the
estrogen or androgen receptor (ER and AR,
respectively), and/or gene in vitro expression
assays. For more reﬁned hazard assessments, a
variety of in vivo rodent assays have been
described, such as the rodent uterotrophic
and Hershberger assays [Endocrine Disruptor
Screening and Testing Advisory Committee
(EDSTAC) 1998; Gray et al. 2002;
Organisation for Economic Co-operation
(OECD) 1998). However, humans and
wildlife are exposed to mixtures of chemicals,
and the best way to determine the sum of the
activities of the individual components of the
mixture, leading to a holistic assessment of
hazard, remains open to discussion. 
There are several approaches to the assess-
ment of mixtures, ranging from the bioassay
of whole mixtures (e.g., Heindel et al. 1994;
Jobling et al. 2002; Rodgers-Gray et al. 2001)
to the more analytical component-based
approaches (e.g., Payne et al. 2001; Silva et al.
2002). In whole-mixture approaches, the
mixture is treated as if it were one single
chemical entity, whereas in the component-
based approach the mixture effects are
derived from consideration of the activities of
the individual constituents of the mixture.
The present multicomponent experiments
can be regarded as a surrogate mixture
approach that lies between the whole-mixture
and component-based approaches (“surro-
gate” because the mixture is re-created in the
laboratory). The surrogate is illustrated by
Heindel et al. (1994, 1995), who tested
reconstituted mixtures of pesticides contain-
ing up to 100 times the concentrations mea-
sured in California and Iowa groundwater.
They found that the mixtures were approxi-
mately as toxic as the most potent compound
in the mixture for reproductive end points.
Other methods include the simple addition
of the individual effects [Waters et al. 1990;
U.S. Environmental Protection Agency
(EPA) 1989], the use of toxic equivalency fac-
tors (TEFs; Nisbet and LaGoy 1992; Safe
1998; Van den Berg et al. 1998), and isobole
analysis in the case of two- or three-compo-
nent mixtures for which knowledge exists
regarding the dose–response relationships of
the individual components of the mixture
(Charles et al. 2002; Chen and Pounds 1998;
Nellemann et al. 2003; Rajapakse et al. 2002;
Tully et al. 2000).
A recent observation of particular interest
is that a mixture of estrogens can cause estro-
genic effects in vitro despite the individual
components of the mixture being present at
concentrations below their individual no
observable effect levels (NOELs) for estro-
genicity in vitro (Payne et al. 2001; Silva et al.
2002). Silva et al. (2002) used the phrase
“something for nothing” in the title of their
paper, thereby galvanizing interest in this
topic. However, Edgren and Calhoun (1960)
observed that the uterotrophic activity of
strong estrogens is inhibited by the concomi-
tant presence of weaker estrogens—an effect
they referred to as biological buffering. Those
data indicate that the observations made by
Silva et al. (2002) in vitro may not automati-
cally translate to the situation prevailing in
estrogen-sensitive tissues in vivo.
The present studies were therefore
designed to evaluate the activity of mixtures of
estrogens using the immature rat uterotrophic
assay. Initial studies were concerned with vari-
ous binary mixtures of the synthetic estrogen
bisphenol A (BPA) and the phytoestrogen
genistein (GEN), using doses that were indi-
vidually active in the assay. These studies were
followed by investigation of a multicompo-
nent mixture of seven estrogenic compounds.
The seven chemicals were selected to include a
range of anthropogenic, synthetic, and plant-
derived estrogens and to cover approximately
a million-fold range of potencies [from
nonylphenol (NP; minimum detection level,
75 mg/kg) to ethinyl estradiol (EE; minimum
detection level, 0.1 µg/kg)] in the immature
rat uterotrophic assay. In those studies mix-
tures were tested such that their components
were present in the mixture at doses that
either gave a small but signiﬁcant uterotrophic
effect, or no effect, when tested individually.
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We have evaluated whether mixtures of estrogens, present in the mix at doses that are individually
inactive in the immature rat uterotrophic assay, can give a uterotrophic response. Seven chemicals
were evaluated: nonylphenol, bisphenol A (BPA), methoxychlor, genistein (GEN), estradiol,
diethylstilbestrol, and ethinyl estradiol. Dose responses in the uterotrophic assay were constructed
for each chemical. The ﬁrst series of experiments involved evaluating binary mixtures of BPA and
GEN at dose levels that gave moderate uterotrophic responses when tested individually. The mix-
tures generally showed an intermediate or reduced uterotrophic effect compared with when the
components of the mixture were tested alone at the dose used in the mixture. The next series of
experiments used a multicomponent (complex) mixture of all seven chemicals evaluated at doses
that gave either weakly positive or inactive uterotrophic responses when tested individually in the
assay. Doses that were nominally equi-uterotrophic ranged over approximately six orders of mag-
nitude for the seven chemicals. Doses of agents that gave a weak uterotrophic response when
tested individually gave a marginally enhanced positive response in the assay when tested com-
bined as a mixture. Doses of agents that gave a negative uterotrophic response when tested indi-
vidually gave a positive response when tested as a mixture. These data indicate that a variety of
different estrogen receptor (ER) agonists, present individually at subeffective doses, can act simul-
taneously to evoke an ER-regulated response. However, translating these ﬁndings into the process
of environmental hazard assessment will be difﬁcult. The simple addition of the observed, or pre-
dicted, activities for the components of a mixture is confirmed here to be inappropriate and to
overestimate the actual effect induced by the mixture. Equally, isobole analysis is only suitable for
two- or three-component mixtures, and concentration addition requires access to dose–response
data and EC50 values (concentration giving 50% of the maximum response) for the individual
components of the mixture—requirements that will rarely be fulﬁlled for complex environmental
samples. Given these uncertainties, we conclude that it may be most expedient to select and bio-
assay whole environmental mixtures of potential concern. Key words: anthropogenic estrogens,
binary mixtures, complex mixtures, estrogenicity, immature rat uterotrophic assay, phytoestrogens,
synthetic estrogens. Environ Health Perspect 112:575–582 (2004). doi:10.1289/ehp.6831 available
via http://dx.doi.org/ [Online 8 January 2004]Materials and Methods
Chemicals. Estradiol (E2; 98+% purity),
diethylstilbestrol (DES; 99+% purity), EE
(98+% purity), and arachis oil (AO; peanut
oil) were purchased from the Sigma
Chemical Company (Poole Dorset, UK). BPA
(99+% purity) was purchased from Aldrich
(Gillingham, Dorset, UK), GEN (98+%
purity) from Ultraﬁne Chemicals (Manchester,
UK), methoxychlor (MXC; ~98% purity)
from ICN (Basingstoke, Hampshire, UK),
and NP (95+% purity) from Schenectady
International (Freeport, TX, USA). All com-
pounds were either homogenized or, in the
case of NP, dissolved, in AO to give the appro-
priate stock solutions. MXC was ground to a
powder using a pestle and mortar before
homogenization in AO. A stock solution of
each compound was prepared at the beginning
of each study. Dosing solutions of the individ-
ual compounds were prepared once at the
beginning of each study by diluting the appro-
priate stock solution, and dosing solutions of
the mixtures were prepared fresh from the
appropriate stock solutions on a daily basis. All
solutions were stored at room temperature
during the course of each study.
Animals. Immature female AP rats
(19–20 days of age) were obtained from the
barriered animal breeding unit (Astrazeneca
Pharmaceuticals, Macclesﬁeld, Cheshire, UK).
They were group housed at a maximum of six
per cage in solid-bottomed polypropylene
cages containing sawdust (Wood Treatments
Ltd., Macclesﬁeld, Cheshire, UK) and shred-
ded paper as bedding for the duration of the
experiment. Fun tubes and houses were pro-
vided as environmental enrichment. All ani-
mals were allowed RM1 diet (Special Diet
Services Ltd., Witham, Essex, UK) and water
ad libitum for the duration of the experiment.
Uterotrophic assay. All animals were
weighed and then were terminated using
an overdose of Halothane (Concord Pharma-
ceuticals Ltd, Dunmow, Essex, UK) followed
by cervical dislocation. All terminations took
place in the morning 24 hr after the last dose.
Animals were removed from study in a
blocked fashion, taking three animals/cage at a
time. The uterus was removed from each ani-
mal, trimmed free of fat, gently blotted, and
weighed as described previously (Odum et al.
1997). Each uterus was placed in a preweighed
vial, dried overnight at 70°C, and then
reweighed to obtain a dry weight measure-
ment. Two people performed the necropsies
while a third weighed all tissues and placed
them into the appropriate vials. This allowed
the termination of up to 180 animals (as in
the ﬁnal study) within 3 hr.
Dosing. Animals were exposed to all com-
pounds (either individually or as a mixture) by
single subcutaneous injection in the morning
of 3 consecutive days using a dosing volume of
5 mL/kg body weight. With the exception of
the first study (experiment 1), which had
group sizes of 12, all other studies had group
sizes of 8. The initial dose levels employed
(detailed in Table 1) were based both on previ-
ously published data and data generated in-
house. High doses were chosen to induce a
clear positive response in the assay, whereas the
lower doses were predicted to be inactive in the
assay—the doses being adjusted during the
course of the experiments to ensure such obser-
vations. For example, the highest dose of BPA
used was 600 mg/kg (experiment 1); this was
reduced to 75 mg/kg in later experiments
(experiments 4–6). Similarly, the lowest dose
of BPA used in the initial studies was
300 mg/kg (experiments 1 and 2), which was
reduced to 30 mg/kg in the third study and
was eventually lowered to 1.5 mg/kg in the
ﬁnal experiment (experiment 6).
Study design. Six studies were performed in
total and these are described in Table 1. The
ﬁrst three experiments were concerned with the
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Table 1. Dose levels used in the six experiments for the individual compounds when tested alone or in mixtures.
Dose levels (per kilogram individually or as component of mixture)
BPA GEN NP MXC E2 DES EE
Experiment number and procedure (mg) (mg) (mg) (mg) (µg) (µg) (µg) Comments
1 BPA and GEN tested individually  300 15 Doses based on OECD validation
600 50 studies (Kanno et al. 2003)
BPA and GEN tested in binary mixtures  300 15
300 50
600 15
600 50
2 BPA and GEN tested individually at all doses shown and in 300 10 BPA dose level maintained at
binary mixtures of 300 mg BPA + GEN at each of the doses  15 300 mg/kg in mixtures while
20 increasing the concentration of
40 GEN; doses based on Kanno et al.
50 (2003)
3 BPA and GEN tested individually at doses shown 30 1 Maintenance of a constant ratio
and in the binary mixtures using a ratio of 30:1 BPA:GEN 75 2.5 between BPA and GEN suggested
150 5 by Kortenkamp (personal 
300 10 communication)
4 α*-Dose for individual compounds and contribution to mixture 75 5 50 50 1 0.05 0.15 Doses for NP, BPA, MXC, and GEN 
α*/2 mixture 37.5 2.5 25 25 0.5 0.025 0.075 based on Kanno et al. (2003); E2
α*/5 for individual compounds and contribution to mixture 15 1 10 10 0.2 0.01 0.03 dose based on Odum et al. (1997); 
DES dose based on in-house data; 
NP, GEN, and DES were inactive 
in the uterus at α* dose
5 α-Dose for individual compounds and contribution to mixture  75 10 75 50 1 0.25 0.1 Individual α* concentration
α/2 mixture 37.5 5 37.5 25 0.5 0.125 0.05 marginally increased for GEN, NP,
α/5 mixture 15 2 15 10 0.2 0.05 0.02 and DES to give α-doses (ensuring
α/10-dose for individual compounds and contribution to mixture 7.5 1 7.5 5 0.1 0.025 0.01 a positive uterotrophic response);
α/20 mixture 3.75 0.5 3.75 2.5 0.05 0.0125 0.005 EE α*-dose marginally reduced to
α/50 mixture 1.5 0.2 1.5 1 0.02 0.005 0.002 give α-dose; E2 active at α/10
6 α-Dose for individual compounds and contribution to mixture 75 10 75 50 1 0.25 0.1 α-Dose for each compound
α/2 mixture 37.5 5 37.5 25 0.5 0.125 0.05 identical to those in experiment 5;
α/5 mixture 15 2 15 10 0.2 0.05 0.02 compounds tested individually at
α/10 mixture 7.5 1 7.5 5 0.1 0.025 0.01 α/50 to ensure absence of
α/20 mixture 3.75 0.5 3.75 2.5 0.05 0.0125 0.005 uterotrophic response
α/50-dose for individual compounds and contribution to mixture 1.5 0.2 1.5 1 0.02 0.005 0.002
α/100 mixture 0.75 0.1 0.75 0.5 0.01 0.0025 0.001interaction between BPA and GEN only
(experiments 1–3, Tables 1 and 2). The initial
study investigated the interaction between
300 or 600 mg/kg BPA and 15 or 50 mg/kg
GEN, with the doses being based on those used
for the OECD uterotrophic validation trials
(Kanno et al. 2003). In the second study, BPA
was maintained at 300 mg/kg and was mixed
with increasing levels of GEN (10–50 mg/kg).
The last of the BPA/GEN studies employed
mixtures consisting of a fixed ratio of 30:1
BPA:GEN (experiment 3, Table 2) as
described by Altenburger et al. (2000) and
Backhaus et al. (2000) and as recommended
by A. Kortenkamp (personal communication).
A complex mixture, consisting of seven
compounds (NP, MXC, BPA, GEN, E2, DES,
and EE) was investigated in the final set of
experiments. The top dose of each mixture
component is referred to as either the α*-dose
in experiment 4 (Tables 1 and 3) or the α-dose
in the last two studies (Tables 1 and 3), with
α* and α being distinct from each other as fol-
lows. In the first complex mixture study
(experiment 4, Tables 1 and 3), the top doses
(α*) were chosen to induce a moderate increase
in blotted uterine weight, based on previously
published data. However, the absence of a pos-
itive response for some of the compounds in
this study led to marginal adjustments of the
top dose levels for the mixture components
(experiment 5, Tables 1 and 3). These highest
concentrations, referred to as α-dose levels,
were also used in the ﬁnal study (experiment 6,
Tables 1 and 3). Several dilutions of both α*
and α were also studied to determine the
NOEL for each mixture component.
Stock solutions of the individual com-
pounds, which were 7-fold more concentrated
than the highest (α*/α) dose to be used, were
diluted to give α, α*, α*/5, α/10, and α/50
dosing solutions for each compound as appro-
priate to the study (Table 1). The highest con-
centration mixture dosing solution (α* for
experiment 4 and α for experiments 5 and 6)
was prepared by homogenizing equal volumes
of the individual 7× concentrated α*/α stock
solutions together. Serial dilutions of this top
mixture gave dosing solutions of α*/2 and
α*/5 for experiment 4 and a series of solutions
ranging from α/2 to α/100 for experiments 5
and 6. EE at 1 µg/kg was used as a maximal
positive response control in all binary and
complex mixture studies.
Statistical analyses. Organ weights were
considered by analysis of variance (ANOVA)
and analysis of covariance (ANCOVA) on ﬁnal
body weight using SAS software (SAS Institute
1999). In addition, organ to body weight ratios
were considered by ANOVA. Statistical out-
comes shown in Tables 2 and 3 and in
Figures 1–6 are based on ANCOVA.
Results
All of the raw data generated have been
recorded in tabular form to allow others to
reanalyze the database. However, in order to
render this complex set of experiments intelligi-
ble, primary reliance has been placed here on
Figures 1–7. We used 1 µg/kg EE as a positive
control in most experiments (Tables 2 and 3).
Full dose–response relationships were estab-
lished for all of the chemicals studied
(Figure 5), and these are consistent with the
available literature for each chemical (Table 1,
Figure 5). Figure 7 compares the observed
increases in blotted uterine weight after expo-
sure to a mixture with the predicted outcome
assuming an additive response. To calculate the
additive effect, the group mean control uterine
weight was subtracted from the group mean
uterine weights recorded for each of the concur-
rent individual components. The resultant val-
ues, as well as the group mean control weight,
were then added together to give a ﬁnal weight,
which represented the predicted outcome.
BPA/GEN studies. Initial studies investi-
gated the estrogenicity of a mixture of BPA
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Table 2. Uterine and body weights (mean ± SD) from ﬁve independent immature rat uterotrophic assays.
Dose  Uterine weight (mg) Final body
Experiment Compound (/kg) Blotted Dry weight (g)
AA O 4   mL 19.4 ± 2.1 51.9 ± 6.7
BPA 10 mg 23.9 ± 3.3 52.1 ± 7.5
100 mg 29.0 ± 3.8 50.8 ± 2.0
300 mg 38.5 ± 6.3 52.6 ± 3.6
600 mg 41.4 ± 7.8 51.5 ± 6.7
800 mg 59.0 ± 8.6 49.6 ± 5.4
BA O 4   mL 17.2 ± 1.5 52.3 ± 6.0
GEN 1 mg 19.7 ± 1.3 51.1± 5.8
15 mg 37.4 ± 7.6 51.9 ± 5.3
35 mg 47.6 ± 9.3 51.1 ± 5.1
50 mg 54.2 ± 9.0 51.6 ± 4.4
80 mg 67.7 ± 8.2 52.6 ± 4.9
EE 0.3 µg 49.3 ± 3.4 50.8 ± 4.5
1.0 µg 91.9 ± 9.1 51.4 ± 3.6
1A O5  mL 21.7 ± 3.6 4.3 ± 0.7 51.1 ± 4.6
BPA 300 mg 40.2 ± 6.1** 7.8 ± 1.0** 50.3 ± 4.7
600 mg 45.8 ± 7.9** 9.1 ± 1.3** 50.9 ± 5.7
GEN 15 mg 51.5 ± 7.1** 9.8 ± 1.0** 50.3 ± 4.5
50 mg 82.8 ± 11.8** 15.0 ± 1.8** 49.3 ± 4.2
EE 1 µg 101.7 ± 9.8** 17.8 ± 1.2** 50.2 ± 5.2
BPA/GEN 300 mg/15 mg 47.6 ± 7.3** 9.9 ± 1.3** 49.7 ± 4.4
300 mg/50 mg 67.7 ± 13.9** 13.0 ± 2.2** 49.4 ± 4.4
600 mg/15 mg 57.9 ± 8.4** 11.6 ± 1.3** 48.7 ± 4.6
600 mg/50 mg 68.3 ± 5.6** 13.0 ± 0.9** 48.9 ± 5.8
2A O5  mL 23.0 ± 2.3 4.2 ± 0.3 54.3 ± 3.3
BPA 300 mg 39.6 ± 8.2** 7.5 ± 2.2** 52.7 ± 3.8
GEN 10 mg 47.4 ± 3.4** 8.4 ± 0.6** 54.3 ± 4.2
15 mg 51.2 ± 10.2** 9.1 ± 1.7** 54.0 ± 4.4
20 mg 60.5 ± 8.7** 10.5 ± 1.6** 54.0 ± 3.4
30 mg 70.1 ± 5.0** 12.2 ± 0.9** 55.0 ± 3.3
40 mg 76.3 ± 9.7** 13.4 ± 1.6** 54.8 ± 4.3
50 mg 86.4 ± 15.0** 14.6 ± 2.3** 54.2 ± 3.9
EE 1 µg 96.7 ± 11.6** 15.6 ± 1.5** 54.0 ± 4.5
BPA/GEN 300 mg/10 mg 50.8 ± 6.8** 9.1 ± 1.1** 54.5 ± 3.0
300 mg/15 mg 46.1 ± 5.8** 8.5 ± 0.9** 53.3 ± 3.8
300 mg/20 mg 56.0 ± 8.9** 9.9 ± 1.4** 52.9 ± 3.8
300 mg/30 mg 64.1 ± 5.7** 11.3 ± 0.9** 54.5 ± 4.7
300 mg/40 mg 65.3 ± 7.0** 11.1 ± 1.1** 53.2 ± 3.2
300 mg/50 mg 66.3 ± 8.8** 11.4 ± 1.6** 53.1 ± 4.8
3A O5  mL 21.8 ± 3.6 4.1 ± 0.6 53.2 ± 3.5
BPA 30 mg 31.7 ± 2.9** 6.2 ± 0.6** 53.2 ± 3.5
75 mg 29.7 ± 3.9** 5.8 ± 0.9** 52.4 ± 4.1
150 mg 32.3 ± 5.0** 6.3 ± 0.9** 51.0 ± 5.5
300 mg 35.2 ± 3.4** 6.8 ± 0.6** 51.5 ± 3.9
GEN 1 mg 23.4 ± 4.7 4.7 ± 1.0 51.7 ± 4.4
2.5 mg 26.9 ± 4.1* 5.3 ± 0.8** 52.6 ± 4.3
5 mg 26.8 ± 2.5* 5.4 ± 0.6** 51.7 ± 3.1
10 mg 44.6 ± 7.4** 8.1 ± 1.5** 54.3 ± 2.5
BPA/GEN 30 mg/1 mg 32.5 ± 2.9** 5.8 ± 0.5** 53.3 ± 4.1
75 mg/2.5 mg 28.9 ± 2.4** 5.1 ± 0.6** 51.7 ± 6.2
150 mg/5 mg 33.1 ± 3.4** 5.8 ± 0.6** 52.4 ± 4.3
300 mg/10 mg 41.0 ± 5.8** 7.4 ± 1.1** 53.1 ± 3.8
Experiments A and B: data generated in this laboratory for the OECD evaluation of the uterotrophic assay (Kanno et al.
2003) and used as part of the dose–response curves (Figure 5). Data from experiments 1–3 were analyzed for statistical
signiﬁcance by both ANOVA and ANCOVA. 
*p < 0.05 and **p < 0.01 by ANCOVA. and GEN (Table 2, Figures 1–3). Signiﬁcant
increases in uterine weight (blotted and dry)
were induced by both compounds adminis-
tered individually, with the lowest active dose
for GEN being 2.5 mg/kg (experiment 3;
Table 2) and that for BPA being 30 mg/kg
(experiment 3; Table 2). In experiment 1
(Figure 1), the mixture of BPA and GEN gave
intermediate uterine weights—greater than
the effect of BPA alone but less than the effect
of GEN alone. In experiment 2 (Figure 2),
addition of a ﬁxed dose of 300 mg/kg BPA to
different doses of GEN (10–50 mg/kg) atten-
uated the GEN dose response, with effects at
the top two doses being signiﬁcantly reduced.
In experiment 3 (Table 2, Figure 3), a fixed
ratio of 30:1 BPA:GEN was evaluated over a
dilution range. The activity of the mixture was
not significantly different from the response
given by BPA alone.
Mixtures of seven compounds. EE (1 µg/kg)
gave a maximum positive uterotrophic
response (both blotted and dry uterine weight)
in all of the complex mixture experiments
(Table 3). Three studies were performed com-
paring the effects on the uterus of a mixture
containing seven compounds (NP, BPA,
MXC, GEN, E2, DES, and EE), with the
effects induced individually by each of the mix-
ture components (Table 3, Figures 4–6). Doses
were based on previously published data or
generated in-house as described in Table 1.
Minor adjustments to these initial dose levels,
as well as the inclusion of additional doses,
allowed dose–response curves for the individ-
ual compounds to be established, and these
showed a high degree of concordance with pre-
viously published data (Figure 5).
In the initial complex mixture study (exper-
iment 4; Table 3, Figure 4), the highest dose for
each of the compounds was chosen to induce a
small, but statistically significant, increase in
uterine blotted weight (the α*-doses, approxi-
mating individual lowest effective dose levels).
The lower individual doses (the α*/5-doses)
were predicted to be inactive in the assay based
on the published dose–response data (Figure 5).
BPA, MXC, E2, and EE individually produced
signiﬁcant increases in uterine weight (blotted
and dry) at the α*-doses (p < 0.01). However,
NP, GEN, and DES failed to increase uterine
weight significantly. No increases in uterine
weight were observed at individual α*/5-doses
(Table 3, Figure 4). Mixtures of the seven com-
pounds at the α*, α*/2, or α*/5 doses each
induced a signiﬁcant increase in uterine weight
relative to the control weights (p < 0.01).
In the subsequent complex mixture studies,
the α*-doses of DES, GEN, and NP were
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Table 3. Uterine and ﬁnal body weight (mean ± SD) of the seven compounds when tested alone or as part
of a mixture.
Dose Contribution Uterine weight (mg)  Final body
Experiment Compound (/kg) to mixture Blotted  Dry weight (g) 
4A O5  mL – 24.2 ± 3.8 4.9 ± 1.0 53.6 ± 5.7
NP 10 mg α*/5 24.2 ± 4.6 4.7 ± 0.7 55.9 ± 10.4
50 mg α* 24.8 ± 4.3 4.9 ± 0.6 54.5 ± 6.8
MXC 10 mg α*/5 23.1 ± 4.2 4.6 ± 0.6 51.0 ± 6.9
50 mg α* 34.5 ± 9.4** 6.4 ± 1.5* 53.7 ± 4.1
BPA 15 mg α*/5 29.0 ± 1.6 5.9 ± 0.4 54.0 ± 4.3
75 mg α* 32.0 ± 4.2* 6.4 ± 0.7** 52.2 ± 6.0
GEN 1 mg α*/5 24.9 ± 5.0 4.9 ± 0.8 52.0 ± 7.2
5 mg α* 26.0 ± 4.9 5.0 ± 1.0 53.3 ± 6.5
E2 0.2 µg α*/5 26.6 ± 6.6 5.2 ± 1.2 52.2 ± 6.0
1.0 µg α* 39.1 ± 9.4** 7.4 ± 1.6** 53.2 ± 6.7
DES 0.01 µg α*/5 23.6 ± 4.5 4.9 ± 0.9 55.3 ± 9.2
0.05 µg α* 28.1 ± 5.7 5.7 ± 1.1 54.3 ± 5.8
EE 0.03 µg α*/5 24.6 ± 4.5 4.9 ± 0.6 54.4 ± 4.4
0.15 µg α* 46.9 ± 7.0** 8.6 ± 1.2** 54.6 ± 4.7
1.0 µg – 116.4 ± 32.1** 20.5 ± 5.1** 52.4 ± 9.2
Mixture α*/5 41.3 ± 5.0** 7.7 ± 0.8** 54.8 ± 6.2
α*/2 49.0 ± 7.2** 9.3 ± 1.4** 53.2 ± 6.7
α* 59.9 ± 4.9** 11.4 ± 0.9** 54.6 ± 5.1
5A O5  mL – 21.7 ± 5.0 4.5 ± 0.8 52.3 ± 6.5
NP 7.5 mg α/10 24.7 ± 4.9 4.9 ± 0.9 54.2 ± 5.5
75 mg α 36.3 ± 8.0** 6.7 ± 1.2** 54.1 ± 6.8
MXC 5 mg α/10 25.3 ± 6.8 4.9 ± 1.2 53.2 ± 5.2
50 mg α 33.3 ± 6.4** 6.3 ± 1.2** 54.1 ± 5.7
BPA 7.5 mg α/10 26.0 ± 3.1 5.3 ± 0.4** 52.3 ± 7.4
75 mg α 33.4 ± 3.8** 6.7 ± 0.8** 53.0 ± 7.6
GEN 1 mg α/10 24.9 ± 5.0 5.0 ± 0.8 54.1 ± 6.6
10 mg α 51.9 ± 6.6** 9.6 ± 1.2** 53.8 ± 7.4
E2 0.1 µg α/10 28.3 ± 8.2* 5.5 ± 1.4 53.9 ± 6.9
1.0 µg α 50.0 ± 9.9** 8.9 ± 1.6** 53.8 ± 5.9
DES 0.025 µg α/10 25.2 ± 6.3 5.4 ± 1.1 53.9 ± 7.1
0.25 µg α 47.9 ± 1.4** 8.5 ± 0.3** 52.3 ± 5.8
EE 0.01 µg α/10 22.3 ± 5.2 4.5 ± 1.3 53.6 ± 8.7
0.1 µg α 31.4 ± 4.8** 5.9 ± 1.0* 55.7 ± 5.9
1.0 µg – 102.7 ± 10.1** 17.1 ± 1.4** 54.9 ± 5.4
Mixture α/50 26.5 ± 5.5 5.5 ± 1.0 54.5 ± 6.9
α/20 28.1 ± 4.8* 5.5 ± 0.9* 51.6 ± 6.5
α/10 37.4 ± 4.1** 7.4 ± 0.7** 53.0 ± 7.0
α/5 44.0 ± 5.2** 8.4 ± 1.0** 52.7 ± 7.2
α/2 49.5 ± 5.3** 9.3 ± 1.2** 53.4 ± 6.6
α 63.0 ± 10.4** 12.0 ± 1.8** 54.0 ± 6.4
6A O5  mL – 23.6 ± 5.3 4.4 ± 0.9 54.5 ± 6.9
NP 1.5 mg α/50 23.7 ± 1.5 4.7 ± 0.2 55.0 ± 6.1
75 mg α 35.7 ± 10.0** 6.7 ± 1.4** 54.3 ± 4.3
MXC 1 mg α/50 23.2 ± 5.9 4.6 ± 1.1 55.0 ± 6.6
50 mg α 32.9 ± 8.6** 6.2 ± 1.4** 55.1 ± 6.8
BPA 1.5 mg α/50 24.4 ± 5.5 4.8 ± 0.9 54.8 ± 5.2
75 mg α 35.3 ± 3.2** 6.9 ± 0.7** 56.2 ± 5.5
GEN 0.2 mg α/50 24.3 ± 7.4 4.5 ± 1.3 54.0 ± 6.9
10 mg α 42.6 ± 4.2** 7.9 ± 0.9** 54.1 ± 6.6
E2 0.02 µg α/50 22.8 ± 3.0 4.3 ± 0.6 54.3 ± 7.5
1.0 µg α 50.6 ± 7.9** 8.6 ± 1.0** 54.8 ± 3.9
DES 0.005 µg α/50 23.4 ± 2.8 4.3 ± 0.5 55.2 ± 6.4
0.25 µg α 45.3 ± 5.9** 7.8 ± 0.9** 54.8 ± 7.4
EE 0.002 µg α/50 25.7 ± 4.7 5.0 ± 0.9 55.9 ± 7.7
0.1 µg α 34.6 ± 5.5** 6.2 ± 0.9** 56.0 ± 6.5
1.0 µg – 98.3 ± 23.8**  16.2 ± 4.3**  55.2 ± 7.9
Mixture α /100 23.0 ± 5.7 4.4 ± 1.0 55.2 ± 7.1
α/50 29.7 ± 6.7* 5.5 ± 1.1* 54.7 ± 6.5
α/20 28.3 ± 3.3 5.4 ± 0.7* 54.7 ± 6.5
α/10 37.1 ± 5.6** 6.8 ± 1.2** 53.5 ± 10.1
α/5 45.3 ± 3.8** 8.5 ± 0.8** 54.8 ± 5.3
α/2 53.4 ± 10.9** 10.0 ± 2.3** 55.4 ± 7.2
α 62.2 ± 9.0** 11.5 ± 1.5** 54.7 ± 5.5
Data were analyzed for statistical signiﬁcance by both ANOVA and ANCOVA. 
*p < 0.05 and **p < 0.01 by ANCOVA. 
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Figure 1. Uterotrophic activity of BPA (300 mg/kg or
600 mg/kg), GEN (15 mg/kg or 50 mg/kg), and mix-
tures of the two compounds. Error bars indicate SD.
Individual compounds and the binary mixtures
induced significant increases (p <0 . 0 1) in blotted
uterine weight (by ANOVA and ANCOVA).increased in order to obtain a positive
response for each when tested individually at
that dose; the α*-dose of EE was also reduced
from 0.15 µg/kg to 0.1 µg/kg. The remaining
three chemicals were maintained at their orig-
inal α*-dose. Given these changes, the top
doses in the next two experiments (experi-
ments 5 and 6; Table 3, Figures 5 and 6) were
referred to as the α-doses, as opposed to
α*-doses (as described in Tables 1 and 3).
In experiment 5 the components were
tested individually at their α- and α/10 doses.
The mixture was tested at the α-dose, and the
α/2, α/5, α/10, α/20 and α/50 doses. All
compounds individually produced signiﬁcant
increases (p < 0.01) in uterine weight (blotted
and dry) at the α-dose (experiment 5; Table 3,
Figures 5 and 6). At the α/10-dose ﬁve chemi-
cals were negative, but a small increase in blot-
ted uterine weight was seen for E2 (p < 0.05;
Figures 5 and 6) and a small increase in dry
uterine weight for BPA (p < 0.01; Figure 6).
Signiﬁcant increases in both blotted and dry
uterine weight were seen for all mixtures down
to the α/20 dose, with no effects being
observed at the α/50-dose in this penultimate
study.
Because both BPA and E2 produced uterine
effects at their α/10 dose levels in experiment 5,
all seven compounds were tested individually at
their α- and α/50 doses in the ﬁnal experiment
(experiment 6; Table 3, Figures 5 and 6). The
mixtures were the same as in experiment 5
(α–α/50) with the addition of an α/100 mix-
ture dose. All compounds individually induced
a significant (p < 0.01) increase in uterine
weight at their α-dose and were inactive at their
individual α/50-dose (blotted and dry; Figures
5 and 6). Significant increases (p < 0.01) in
uterine weight (blotted and dry) were recorded
for the mixtures at α/10 dose levels and above.
Increases were also seen for the dry weight
measurements of both the α/20 and the α/50
mixture doses (experiment 6; Table 3,
Figure 6). In addition, a significant increase
(p < 0.05) in uterine blotted weight was
recorded for the α/50 mixture dose. No effects
were observed at the α/100 mixture dose.
The data in Figures 5 and 6 reveal that, in
general, effects considered to be statistically
insignificant are marginally greater than the
concurrent control levels. To evaluate if the
effects of mixture doses merely reflected the
sum of the significant or nonsignificant
increases seen for the individual components
of the mixture, these individual increases were
summed, added to the control level, and
shown as a “predicted” effect in Figure 7. Such
additions represent an invalid method of pre-
dicting the activity of mixtures (Berenbaum
1981, 1989; Kortenkamp and Altenburger
1998), but because they are likely to be
employed by others, the method was evaluated
again here. This additive approach led to an
overestimation of the ﬁnal outcome in most of
the cases (binary mixtures experiments 1–3
and complex mixtures at α*, α/10, and
α-dose levels in experiments 4–6). In a few
cases, the additivity approach led to a slight
underestimation of the observed outcome
(α*/5 mixture of experiment 4; α/50 mixture
of experiment 6). There was only one situa-
tion where the prediction outcome matched
the observed data (30:1 BPA:GEN mixture of
experiment 3).
Discussion
The present studies were conducted using large
group sizes to increase the chance of observing
small changes in mean uterine weight. This,
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Figure 2. Uterotrophic activity of a dose range of GEN in the presence or absence of 300 mg/kg BPA. Error
bars indicate SD. Data were analyzed for statistical signiﬁcance by both ANOVA and ANCOVA. 
**p < 0.01 by ANCOVA. A signiﬁcant increase (p < 0.01) in blotted uterine weight was observed for BPA alone and for all
individual doses of GEN. In addition, all BPA/GEN mixtures produced a signiﬁcant increase (p < 0.01) in uterine weight rel-
ative to BPA alone. The mixtures produced reductions in uterine weight relative to the appropriate dose of GEN; results
for the 40 and 50 mg/kg doses were statistically signiﬁcant, as shown above. 
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Figure 3. Uterotrophic assay dose–response curves
for BPA (30–300 mg/kg), GEN (1–10 mg/kg), and dilu-
tions of a 30:1 mixture of BPA and GEN. Error bars
indicate SD. Data were analyzed for statistical sig-
nificance by both ANOVA and ANCOVA. With the
exception of 1 mg/kg GEN (labeled “a”), both com-
pounds induced a significant increase in blotted
uterine weight, either individually or as a mixture;
(p < 0.05 for 2.5 and 5 mg/kg GEN; p < 0.01 for top
dose of GEN, all mixtures and all doses of BPA).
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Figure 4. Uterotrophic activity of individual chemicals and their mixtures (experiment 4; Table 3) shown as
(A) blotted uterine weight and (B) uterine dry weight. Error bars indicate SD. The top dose (α*) of each
compound was based on Table 1 and was chosen to induce a weak increase in uterine weight. Data were
analyzed for statistical signiﬁcance by both ANOVA and ANCOVA. 
*p < 0.05 and **p < 0.01 by ANCOVA. coupled to the large size of the total database
(836 individual data points), and the repeat
studies conducted, enables the properties of
mixtures of estrogens in vivo to be considered
visually by reference to Figures 1–7. Nonethe-
less, all of the data are presented in tabular
form to enable others to conduct alternative
statistical analyses. 
The uterotrophic potency of the seven
chemicals used in these studies varied by more
than 1,000,000-fold (Figure 5). The derivation
of nominally equi-uterotrophic doses for the
individual agents was therefore a critical
requirement for these experiments. For exam-
ple, the positive α-dose complex mixture con-
tained equi-uterotrophic doses of NP
(75 mg/kg) and EE (0.1 µg/kg)—to mix each
chemical at 75 mg/kg would have generated a
maximal positive uterotrophic response
because of the dominance of the EE dose.
Likewise, to mix them at 0.1 µg/kg would not
have significantly affected the original EE
response because of the absence of uterotrophic
activity for NP at that dose.
The average control uterine blotted weights
for these experiments was approximately
20 mg, and the maximum uterine weight pos-
sible for the assay was approximately 100 mg
(as induced by 1 µg/kg EE). Thus, the reach of
the assay involves a maximum of a 5-fold
increase in uterine weight. In the first two
binary mixture experiments (Figures 1 and 2),
the individual components gave medium
uterotrophic responses, yielding 2- to 4-fold
increases in uterine weight (uteri weighing
between 40 and 80 mg). Under these condi-
tions the mixtures generally gave an intermedi-
ate or reduced uterotrophic response compared
with those of the individual components.
The third binary mixture experiment used
individual dose levels giving only an approxi-
mately 2-fold increase in uterine weight, and
the mixture of BPA and GEN was kept at a
constant ratio of 30:1 (Figure 3). The response
given by dilutions of the mixture was the same
as that given by BPA alone, except for at the
highest dose, where the response was midway
between those given individually by BPA and
GEN. Given the absence of additive effects in
these experiments, the remaining experiments
were designed to evaluate the properties of
mixtures whose constituents were present at
doses that were either weakly active, or inac-
tive, in the assay when tested alone (the situa-
tion most likely to prevail in environmentally
relevant mixtures).
Based on the individual chemical dose–
response data shown in Figure 5, an attempt
was made to select individual doses that would
be either weakly uterotrophic or non-
uterotrophic (the α*- and α*/5 doses, respec-
tively; Figure 4). The α*-doses of NP, GEN,
and DES selected were too low to trigger
uterotrophic responses, and all of the α*/5
doses were inactive. Mixtures of the α*, α*/2,
and α*/5 were clearly uterotrophic, in terms of
both blotted and dry uterine weight (Figure 4).
The α*-dose mixture gave only a marginally
higher response than did the individual com-
ponents, consistent with the earlier binary mix-
ture data (Figures 1–3). Nonetheless, the effect
of the α*-dose mixture was signiﬁcantly higher
(p < 0.01) than the highest effect of the indi-
vidual α* responses (EE). The positive
response given by the α*/5 dose mixture, with
each of the individual components at α*/5
doses being inactive, clearly established the
potential of the effects reported by Silva et al.
(2002) in vitro to be seen also in vivo. The ﬁnal
two experiments were designed to elaborate
this finding using greater dilutions (lower
doses) of the mixture and with adjustments to
the α*-doses of NP, GEN, and DES for them
to be individually positive.
The revised α*-doses shown in Figures 5
and 6 are hereafter referred to as the α-doses,
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Figure 5. (A) Dose–response curves derived for the seven compounds used in experiments 1–6. These dose
responses are compared either with previously published data: NP, BPA, MXC, and GEN (Kanno et al. 2003);
EE (Kanno et al. 2001); E2 (Odum et al. 1997); and DES (in-house data). (B) Uterotrophic data from experi-
ment 5. (C) Uterotrophic data from experiment 6. Error bars indicate SD. The concentrations deﬁned as α,
α/10, and α/50 are highlighted because these were investigated both in mixtures and as individual agents
(experiments 5 and 6; Table 3). Data were analyzed for statistical signiﬁcance by both ANOVA and ANCOVA. 
*p < 0.05 and **p < 0.01 by ANCOVA. and each gave a positive uterotrophic response
(p < 0.01). With two exceptions, the individ-
ual α/10 doses (experiment 5) were nonutero-
trophic. These exceptions were the blotted
uterine weight for the α/10 dose of E2 and the
dry uterine weight for the α/10 dose of BPA
(both p < 0.05). The α/50 individual doses
were all non-uterotrophic (experiment 6).
The dose-related uterotrophic response (both
blotted and dry uterine weights) given by the
mixtures extended to the α/20 dose in experi-
ment 5 and to the α/50 dose in experiment 6.
The fact that the α/50 mixture dose was
active in experiment 6, yet inactive in experi-
ment 5, and that the α/20 mixture dose was
active in experiment 5 but inactive in experi-
ment 6, probably reflects the fact that the
uterotrophic responses in that region are very
weak and are slipping in and out of statistical
signiﬁcance. Nonetheless, these mixture data
conﬁrm that uterotrophic effects can be seen
for mixtures of chemicals under conditions
where the doses of the components of the
mixture are nonuterotrophic.
The data shown in Figure 7 conﬁrm that
the addition of individual uterotrophic
responses for chemicals does not provide a
useful estimate of the likely uterotrophic activ-
ity of the mixture—the greater the magnitude
of the uterotrophic responses being summed,
the greater becomes the overestimate of the
predicted response for the mixture—an effect
referred to by Edgren and Calhoun (1960) as
“biological buffering.” These data therefore
conﬁrm earlier demonstrations of the inappro-
priateness of this approach (Berenbaum 1981,
1989; Kortenkamp and Altenburger 1998). 
The present data have conﬁrmed that it is
legitimate to consider the potential hazard
posed by exposure to mixtures, even though
the components of the mixture may be present
at individually inactive doses. At the molecular
level these data indicate that a variety of ER
agonists can act simultaneously to evoke an
ER-regulated response once a critical concen-
tration of the combined agonists is reached.
This would be consistent with the observation
that at least 10–20% of uterine ERs must be
occupied for at least 4–6 hr in order to stimu-
late sustained uterine hyperplasia (Anderson
et al. 1972, 1975; Clark and Peck 1979; Lan
and Katzenellenbogen 1976). However, trans-
lating this ﬁnding into the process of environ-
mental hazard assessment will be difﬁcult. The
greatest problem will be assessing the individ-
ual potency of the components of a mixture.
For example, the potency of the seven chemi-
cals used in these studies varied by approxi-
mately 1,000,000-fold. Further, it is conﬁrmed
here that the simple addition of the individual
activities of the components of a mixture will
overestimate the actual effect induced by the
mixture. Equally, the most detailed of methods
for combining effects, isobole analysis, is only
suitable for two- or three-component mixtures.
Given these uncertainties, we conclude that it
may be most expedient to select and bioassay
whole mixtures of potential concern in the
environment, as illustrated by the studies by
Rodgers-Gray et al. (2001) and Jobling et al.
(2002).
Finally, consideration of the potential
activity of mixtures is not unique to estrogenic-
ity. The potential hazard posed by occupa-
tional/environmental exposure to carcinogenic
and/or mutagenic mixtures has been studied
(Ashby and Kettle 1987; Ashby et al. 1988;
Feron et al. 2001; Krewski and Thomas 1992;
Lagorio et al. 2000; Salamone et al. 1979;
Taylor et al. 1995), as has the carcinogenicity
to rodents of complex mixtures of carcinogens
(Ito et al. 1969; Lijinski et al. 1983; Takayama
et al. 1989). Experience gained in these other
areas may prove useful when considering the
potential activities of mixtures of estrogens.
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Figure 6. Comparison of blotted uterine weights with dry uterine weights for (A) experiment 5 and (B) experiment 6 (Table 3 and Figure 5). Error bars indicate SD.
Data were analyzed for statistical signiﬁcance by both ANOVA and ANCOVA. Mixtures, whose individual components were not evaluated, are shown as gray bars.
*p < 0.05 and **p < 0.01 by ANCOVA. 
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Figure 7. Comparison of observed responses for the mixtures shown with predicted outcomes. The predicted
outcomes were calculated assuming additivity and represent the sum of the increases in uterine weight over
concurrent controls for the components of a mixture plus one control weight.
†Observed mixture responses are signiﬁcantly different from the concurrent control (p < 0.05 or p < 0.01 as described in
Tables 2 and 3). 
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